GeoVax Labs, Inc. (GOVX) Earnings
GeoVax Labs, Inc. is expected to report next earnings on November 12, 2026 (in NaN days), with a consensus EPS estimate of $-1.03. GOVX has beaten EPS estimates in 4 of its last 12 reported quarters (average surprise -3.5% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jul 27, 2026 | $-2.16 | $-0.97 | +55.1% | — | — |
| May 14, 2026 | $-1.60 | $-2.62 | -63.7% | — | — |
| Nov 13, 2025 | $-6.00 | $-7.75 | -29.2% | — | — |
| May 1, 2025 | $-0.59 | $-0.45 | +23.7% | $2M | +346.4% |
| Mar 27, 2025 | $-0.79 | $-0.30 | +62.0% | $864415 | -63.7% |
| Feb 29, 2024 | $-2.78 | $-13.60 | -389.2% | — | — |
| May 4, 2023 | $-2.85 | $-2.25 | +21.1% | — | — |
| Mar 8, 2023 | $-0.20 | $-2.24 | -1020.0% | — | — |
| Nov 9, 2022 | $-1.80 | $-2.55 | -41.7% | — | — |
| Aug 3, 2022 | $-0.32 | $-2.70 | -743.8% | — | — |
| Mar 9, 2022 | $-0.40 | $-33.58 | -8295.0% | $164962 | — |
| Nov 11, 2021 | $-0.37 | $-4.65 | -1156.8% | $30414 | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q3 FY2025 · November 13, 2025
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- GeoVax remains confident in the progress of its portfolio including GEO-MVA, GEO-CM04S1, Gedeptin, and MVA manufacturing process. - GEO-MVA received EMA expedited development path, allowing bypass of Phase I/II trials to Phase III immuno-bridging trial; fill/finish of clinical batch vaccine material initiated. - GEO-CM04S1 is a critical COVID-19 vaccine for immunocompromised populations, with clinical results presented at various conferences and continued partnering interest. - Gedeptin's Phase II trial for head and neck cancer is pending completion of product manufacturing, with protocol modified to mimic KEYNOTE-689 study using neoadjuvant Gedeptin and pembro. - Increased partnering and collaboration interest from industry and nondilutive funding organizations.
Guidance
- Anticipate advancing GEO-MVA to clinical evaluation early next year. - Focus on advancing GEO-CM04S1 for immune-compromised populations. - Progress Gedeptin Phase II trial for head and neck cancer. - Explore strategies like strategic partnerships, nondilutive funding, or additional stock offerings to fund programs and extend cash runway.
Segment performance
For the 9 months ended September 30, 2025, revenues were $2.5 million compared to $3.1 million in 2024. Research and development expense for Q3 2025 was $5 million vs. $7.4 million in 2024. General and administrative expense for Q3 2025 was $1.3 million vs. $1.2 million in 2024. Net loss for Q3 2025 was $6.3 million vs. $5.8 million in 2024. Year-to-date net loss was $17 million vs. $16.7 million in 2024. Cash balances at September 30 were $5 million.
Risks & headwinds
- Uncertainty in developing and manufacturing product candidates with desired characteristics. - Dependence on regulatory approvals for product licensing and marketing. - Competition from other products that may be more effective or easier to use. - Need to raise required capital to complete development of products. - Dependence on favorable manufacturing and distribution agreements.
Analyst Q&A
Q: Can you envision any scenario where MVA would go commercial before clinical trials?
A: David Dodd stated he wouldn't anticipate prior clinical evaluation, but emergency use licensing via WHO could occur in certain situations.
Q: On broad strategic level, any info on collaborations?
A: David Dodd mentioned holding worldwide rights, active in partnering discussions at conferences, open to win-win partnerships for regional development.
Q: Which regions are most supportive for vaccine programs?
A: GEO-MVA has focus in Southern Hemisphere with endemic outbreaks; CM04S1 targets immunocompromised populations globally; Gedeptin interests solid tumor cancer parties; urgency around GEO-MVA drives much interest.
Q: On Gedeptin and pembro combo, biosimilar of pembro and impact on adoption?
A: David Dodd said he doesn't know if biosimilars will be available by approval, but open to discussions with other immune checkpoint inhibitor developers.